Targeting IL-17 and TH17 cells in chronic inflammation
The DOI matches its Crossref record; 169 of the 169 references it cites were found in a registry or an index.
Abstract
The key role of interleukin-17 (IL-17) and T helper 17 (T(H)17) cells in tissue inflammation, autoimmunity and host defence led to the experimental targeting of these molecules in mouse models of diseases as well as in clinical settings. Moreover, the demonstration that IL-17 and T(H)17 cells contribute to local and systemic aspects of disease pathogenesis, as well as the finding that the IL-17-T(H)17 cell pathway is regulated by IL-23, prompted the identification of inhibitors. These inhibitors include biotechnology products that target IL-23 as well as the leading member of the IL-17 family, IL-17A, and one of its receptors, IL-17 receptor A. Several clinical trials of these inhibitors are underway, and positive results have been obtained in psoriasis, rheumatoid arthritis and ankylosing spondylitis. This Review focuses on the current knowledge of the IL-17-T(H)17 cell pathway to better understand the positive as well as potential negative consequences of targeting them.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abs against IL-17/IL-17RA are in clinical trials for other autoimmune conditions [55].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [55]
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Transforming growth factor-β induces development of the TH17 lineage
Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., & Weaver, C. T. (2006) · Nature · doi:10.1038/nature04754 · Cited by 3,087
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Research works printed but not linked: 1
- Baeten, D. et al. The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum. 62, Abstract L3847 (2010).
Cited by
Items 201–300 of 1,000
Wang, L., Wang, J., Jin, Y., Gao, H., & Lin, X. (2013) · Journal of Periodontology · doi:10.1902/jop.2013.130132 · Cited by 87
Quandt, D., Rothe, K., Scholz, R., Baerwald, C., & Wagner, U. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093293 · Cited by 95
“IFNc is a key cytokine driving the autoimmune response in RA [23,32].”
BackgroundAlinejad, V., Somi, M. H., Baradaran, B., Akbarzadeh, P., Atyabi, F., Kazerooni, H., Kafil, H. S., Maleki, L. A., Mansouri, H. S., & Yousefi, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.06.037 · Cited by 85
Recent progress on nuclear receptor RORγ modulators
Cyr, P., Bronner, S. M., & Crawford, J. J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.08.012 · Cited by 90
Olesch, C., Ringel, C., Brüne, B., & Weigert, A. (2017) · Mediators of Inflammation · doi:10.1155/2017/6059203 · Cited by 89
“Its potency to reduce neutrophil numbers in mice and humans and to limit Th17 polarization may render it an attractive target to interfere with diseases characterized by these features [91, 92].”
BackgroundBrucklacher-Waldert, V., Ferreira, C., Stebegg, M., Fesneau, O., Innocentin, S., Marie, J. C., & Veldhoen, M. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.052 · Cited by 87
“Th17 cells have been closely associated with immunopathology in disorders such as rheumatoid arthritis (RA), multiple sclerosis (MS), lupus erythematosus, psoriasis, graft versus host disease, and inflammatory bowel disease (IBD) and hence are a major therapeutic target (Miossec and Kolls, 2012).”
BackgroundIL-17 Suppresses Immune Effector Functions in Human Papillomavirus-Associated Epithelial Hyperplasia
Gosmann, C., Mattarollo, S. R., Bridge, J. A., Frazer, I. H., & Blumenthal, A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400216 · Cited by 86
Zhao, K., Li, R., Wu, X., Zhao, Y., Wang, T., Zheng, Z., Zeng, S., Ding, X., & Nie, H. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03976-8 · Cited by 84
“It has been reported that IL-6 can promote Th17 cells differentiation from naïve CD4 T cells [28–30], and Th17 cells can induce an inflammatory response through the production of IL-17A and IL-17F [31], which act as key cytokines for neutrophils migration, recruitment and activation [32, 33].”
BackgroundChen, B., Deng, Y. L., Tan, Y., Qin, J., & Chen, L. (2013) · Journal of International Medical Research · doi:10.1177/0300060513501751 · Cited by 83
Biological effects of IL-21 on different immune cells and its role in autoimmune diseases
Gharibi, T., Majidi, J., Kazemi, T., Dehghanzadeh, R., Motallebnezhad, M., & Babaloo, Z. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.09.021 · Cited by 87
Wang, W.-B., Yen, M.-L., Liu, K.-J., Hsu, P.-J., Lin, M.-H., Chen, P.-M., Sudhir, P.-R., Chen, C.-H., Chen, C.-H., Sytwu, H.-K., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.07.013 · Cited by 81
“Known also as Th17 cells, this T helper cell subpopulation is important in mediating host responses toward microbial infections, as well as participating in the pathogenesis of many autoimmune and chronic inflammatory diseases that had been long believed to be caused by Th1 cells (Miossec and Kolls, 2012).”
BackgroundInfluentialNovel Inflammatory Pathways in Periodontitis
Hajishengallis, G., & Sahingur, S. E. (2014) · Advances in Dental Research · doi:10.1177/0022034514526240 · Cited by 91
“Furthermore, IL-17 can mediate the destruction of connective tissue and bone resorption by inducing the expression of matrix metalloproteases and the osteoclastogenic factor RANK ligand (Eskan et al., 2012; Miossec and Kolls, 2012).”
BackgroundStrle, K., Sulka, K. B., Pianta, A., Crowley, J. T., Arvikar, S. L., Anselmo, A. N., Sadreyev, R. I., & Steere, A. C. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix002 · Cited by 87
Pulmonary toxicity of immune checkpoint immunotherapy
Ghanbar, M., & Suresh, K. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170503 · Cited by 88
“IL-17A has been implicated in other autoimmune disorders (114), acute lung injury (115), and lung fibrosis (116), which implies that it may also contribute to the pathogenesis of CIP.”
BackgroundGoepfert, A., Lehmann, S., Blank, J., Kolbinger, F., & Rondeau, J.-M. (2020) · Immunity · doi:10.1016/j.immuni.2020.02.004 · Cited by 75
Moran, E. M., & Mastaglia, F. L. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12445 · Cited by 79
Inhibiting RORγt/Th17 axis for autoimmune disorders
Isono, F., Fujita-Sato, S., & Ito, S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.04.012 · Cited by 82
Targeting transcription factors by small compounds—Current strategies and future implications
Hagenbuchner, J., & Ausserlechner, M. J. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.006 · Cited by 81
Inflammatory Biomarkers Profile as Microenvironmental Expression in Keratoconus
Ionescu, C., Corbu, C. G., Tănase, C., Jonescu-Cuypers, C. P., Nicula, C. A., Dăscălescu, D. M. C., Cristea, M., & Voinea, L. (2016) · Disease Markers · doi:10.1155/2016/1243819 · Cited by 79
Chronic Inflammation in Skin Malignancies
Tang, L., & Wang, K. (2016) · Journal of Molecular Signaling · doi:10.5334/1750-2187-11-2 · Cited by 86
IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation
Raucci, F., Iqbal, A. J., Saviano, A., Minosi, P., Piccolo, M., Irace, C., Caso, F., Scarpa, R., Pieretti, S., Mascolo, N., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104351 · Cited by 84
Cao, Z., Liu, Y., Zhang, Z., Yang, P. B., Li, Z.-G., Song, M., Qi, X., Han, Z., Pang, J., Li, B.-C., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00706-4 · Cited by 87
Wu, N., Wang, Y., Wang, K., Zhong, B., Liao, Y., Liang, J., & Jiang, N. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05215-8 · Cited by 85
“Interleukin-17 (IL-17) is a critical proinflammatory cytokine that is mainly secreted by immune cells, including γδ T cells, NK cells, and TH17 cells [8].”
BackgroundThe Perfect Storm: COVID-19 Health Disparities in US Blacks
Phillips, N., Park, I.-W., Robinson, J. R., & Jones, H. P. (2020) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-020-00871-y · Cited by 80
The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases
Țiburcă, L., Bembea, M., Zaha, D. C., Jurcă, A. D., Vesa, C. M., Rațiu, I. A., & Jurca, C. M. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44050127 · Cited by 85
“At the same time, IL-17A induces the expression of matrix metalloproteinases in fibroblasts, and endothelial and epithelial cells promote the destruction of both connective tissue and bone [33,35].”
BackgroundLiu, C., Zhu, L., Fukuda, K., Ouyang, S., Chen, X., Wang, C., Zhang, C.-J., Martin, B. N., Gu, C., Qin, L., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aaf8823 · Cited by 83
“INTRODUCTION Interleukin-17A (IL-17A) is a signature cytokine of T helper 17 (TH17) cells, a CD4 T cell subset that regulates tissue inflammatory responses (1).”
BackgroundThe AP-1 transcription factor JunB is required for Th17 cell differentiation
Yamazaki, S., Tanaka, Y., Araki, H., Kohda, A., Sanematsu, F., Arasaki, T., Duan, X., Miura, F., Katagiri, T., Shindo, R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17597-3 · Cited by 71
IL-17 in wound repair: bridging acute and chronic responses
Mu, X., Gu, R., Tang, M., Wu, X., He, W., & Nie, X. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01668-w · Cited by 85
“The pro-inflammatory cytokine known as interleukin-17 (IL-17) plays a role in the development of a wide range of disorders, including psoriasis, rheumatoid arthritis, and ankylosing spondylitis [15, 16].”
BackgroundPromising Biomarkers of Radiation-Induced Lung Injury: A Review
Liu, X., Shao, C., & Fu, J. (2021) · Biomedicines · doi:10.3390/biomedicines9091181 · Cited by 79
“The activation of the IL-6/TGF-β/IL-17 signaling pathway is involved in radiation-induced severe fibrosis [74,75].”
BackgroundRzepecka, J., Pineda, M. A., Al-Riyami, L., Rodgers, D. T., Huggan, J. K., Lumb, F. E., Khalaf, A. I., Meakin, P. J., Corbet, M., Ashford, M. L., et al. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.04.005 · Cited by 76
“For example, whilst IL-17 is secreted in high levels during the initiation phase of arthritis, this production is much reduced at the chronic stage [82].”
BackgroundHu, J., Yang, Z., Li, X., & Lü, H. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0630-7 · Cited by 79
“Miossec and Kolls concluded that IL-17 also induces production of CCL20, IL-1β, and TNFα, which implicates IL-17 in the exacerbation of inflammatory responses [38].”
Association of Psoriatic Disease With Uveitis
Egeberg, A., Khalid, U., Gislason, G., Mallbris, L., Skov, L., & Hansen, P. R. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1986 · Cited by 74
Carvalho, A. L., & Hedrich, C. M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.662047 · Cited by 81
“Thus, in humans and mice, dysbiosis and intestinal inflammation can result in alterations in the expression of miRNA-146a (Runtsch et al., 2015; Mirzakhani et al., 2020), which activates inflammatory Frontiers in Molecular Biosciences | www.frontiersin.org 11 April 2021 | Volume 8 | Article 662047”
BackgroundRobert, M., & Miossec, P. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00694-9 · Cited by 75
“TNFα plays a role in lymphoid organ development and organization38–40 and binds to two different receptors: TNR-receptor (TNF-R) I and TNF-RII.41 Lymphotoxin (LT) α−/− (LT is also called TNF-ß) mice have a complete absence of lymph nodes and Peyer’s patches link to defective lymphoid tissue organogenesis.42 Other mole…”
BackgroundSelf-citationGao, H., Liu, L., Zhao, Y., Hara, H., Chen, P., Xu, J., Tang, J., Wei, L., Li, Z., Cooper, D. K. C., et al. (2017) · Xenotransplantation · doi:10.1111/xen.12291 · Cited by 74
Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis
Ferreira, M. C., Whibley, N., Mamo, A. J., Siebenlist, U., Chan, Y. R., & Gaffen, S. L. (2014) · Infection and Immunity · doi:10.1128/iai.01389-13 · Cited by 72
Molecular pathogenesis of genetic and sporadic aortic aneurysms and dissections
Shen, Y. H., & LeMaire, S. A. (2017) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2017.01.001 · Cited by 82
Comprehensive TCR repertoire analysis of CD4+ T-cell subsets in rheumatoid arthritis
Jiang, X., Wang, S., Zhou, C., Wu, J., Jiao, Y., Lin, L., Lü, X., Yang, B., Zhang, W., Xiao, X., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102432 · Cited by 102
Wang, Y., Lou, D. W., Li, D., Jiang, W., Dong, J., Gao, W., & Chen, H. (2020) · Oncology Letters · doi:10.3892/ol.2020.11618 · Cited by 75
“IL‐17A has been extensively studied as a crucial inflammatory cytokine, which is associated with autoimmune conditions (33,34).”
BackgroundInterleukin‐17—A multifaceted cytokine in viral infections
Sahu, U., Biswas, D., Prajapati, V. K., Singh, A. K., Samant, M., & Khare, P. S. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30471 · Cited by 80
Wang, Q., Yang, X., Yuan, R., Shen, A., Wang, P., Li, H., Zhang, J., Tian, C., Jiang, Z., Li, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46130-0 · Cited by 79
Pandya, J. M., Lundell, A., Hallström, M., Andersson, K. M., Nordström, I., & Rudin, A. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5a0116-025r · Cited by 77
The role of IL17B-IL17RB signaling pathway in breast cancer
Alinejad, V., Dolati, S., Motallebnezhad, M., & Yousefi, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.120 · Cited by 77
P38/ERK MAPK signaling pathways are involved in the regulation of filaggrin and involucrin by IL-17
Tan, Q., Yang, H., Liu, E., & Wang, H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7689 · Cited by 75
“Therefore, inhibiting the activity of IL-17 may be a treatment option for patients with chronic inflammatory diseases (30), including AD, restoring barrier function (31).”
BackgroundKono, M., Ochida, A., Oda, T., Imada, T., Banno, Y., Taya, N., Masada, S., Kawamoto, T., Yonemori, K., Nara, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00061 · Cited by 78
Hirsova, P., Bamidele, A. O., Wang, H., Povero, D., & Revelo, X. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.760860 · Cited by 70
“Although Th17 cells show protective functions against bacteria and fungi infections, excessive release of Th17 cytokines has been implicated in chronic inflammation (58).”
BackgroundNeutrophil extracellular traps and pulmonary fibrosis: an update
Yan, S., Li, M., Liu, B., Ma, Z., & Yang, Q. (2023) · Journal of Inflammation · doi:10.1186/s12950-023-00329-y · Cited by 77
“IL-17A acts as a pro-inflammatory factor that promotes PF by depending on NETs [51, 87].”
BackgroundAdvances in the study of IL-17 in neurological diseases and mental disorders
Lu, Y., Zhang, P., Xu, F., Zheng, Y., & Zhao, H. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1284304 · Cited by 82
“This domain is expressed similarly to IL-17R and appears to be associated with IL-1 and “TIR” (Toll/IL-1R) structural domains (22).”
BackgroundThe role of IL-17 in psoriasis
Malakouti, M., Brown, G. E., Wang, E., Koo, J. Y. M., & Levin, E. C. (2014) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.879093 · Cited by 81
Hajishengallis, G., Li, X., Divaris, K., & Chavakis, T. (2022) · Periodontology 2000 · doi:10.1111/prd.12421 · Cited by 76
Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8
Wu, X., Xia, T., Shin, W.-J., Yu, K.-M., Jung, W., Herrmann, A., Foo, S., Chen, W., Zhang, P., Lee, J., et al. (2022) · mBio · doi:10.1128/mbio.00402-22 · Cited by 82
Váraljai, R., Zimmer, L., Al-Matary, Y. S., Kaptein, P., Albrecht, L. J., Shannan, B., Brase, J. C., Gusenleitner, D., Amaral, T. M. S., Wyss, N., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00610-2 · Cited by 75
Gasdermin D-mediated keratinocyte pyroptosis as a key step in psoriasis pathogenesis
Lian, N., Chen, Y., Chen, S., Zhang, Y., Chen, H., Yang, Y., Gu, H., Chen, Q., Li, M., & Chen, X. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06094-3 · Cited by 76
Rutz, S., Eidenschenk, C., Kiefer, J. R., & Ouyang, W. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.07.004 · Cited by 73
Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist
Li, Q., Liu, W., Gao, S., Mao, Y., & Xin, Y. (2021) · BMC Immunology · doi:10.1186/s12865-021-00401-3 · Cited by 75
Gege, C. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1262350 · Cited by 74
“ease, autoimmune uveitis and steroid-resistant asthma [3,4].”
Th17 plasticity: pathophysiology and treatment of chronic inflammatory disorders
Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., & Annunziato, F. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.06.004 · Cited by 70
Impact of chronic and acute academic stress on lymphocyte subsets and monocyte function
Maydych, V., Claus, M., Dychus, N., Ebel, M., Damaschke, J., Diestel, S., Wolf, O. T., Kleinsorge, T., & Watzl, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188108 · Cited by 77
Zhang, Q., Du, X., Li, H., Jiang, Y., Zhu, X., Zhang, Y., Niu, Y., Liu, C., Ji, J. S., Chillrud, S. N., et al. (2022) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2022.129031 · Cited by 69
IL-17: an important pathogenic factor in endometriosis
Shi, J., Zheng, Z., Chen, M., Shen, H., Li, M., & Shao, J. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.71972 · Cited by 84
“While the other four IL-17 isoforms only exist as homodimers [3, 22, 18, 23].”
BackgroundOlsson, R. I., Xue, Y., von Berg, S., Aagaard, A., McPheat, J., Hansson, E. L., Bernström, J., Hansson, P., Jirholt, J., Grindebacke, H., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201500432 · Cited by 70
Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis
Whibley, N., Tritto, E., Traggiai, E., Kolbinger, F., Moulin, P., Brees, D., Coleman, B. M., Mamo, A. J., Garg, A. V., Jaycox, J. R., et al. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.4a0915-428r · Cited by 65
“Drugs targeting IL-17A and IL-17RA have shown efficacy for autoimmune psoriasis, psoriatic arthritis, and ankylosing spondylitis [1, 59].”
BackgroundInterleukin‐17 regulates matrix metalloproteinase activity in human pulmonary tuberculosis
Singh, S., Maniakis‐Grivas, G., Singh, U. K., Asher, R., Mauri, F. A., Elkington, P. T., & Friedland, J. S. (2017) · The Journal of Pathology · doi:10.1002/path.5013 · Cited by 66
“Several biologics such as monoclonal antibodies that neutralize IL-17 signalling are now in clinical development [64,65].”
BackgroundConcise Review: Tissue Engineering of Urinary Bladder; We Still Have a Long Way to Go?
Adamowicz, J., Pokrywczyńska, M., van Breda, S. V., Kloskowski, T., & Drewa, T. A. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0101 · Cited by 66
New Drugs and Treatment Targets in Psoriasis
Kofoed, K. F., Skov, L., & Zachariae, C. O. C. (2015) · Acta Dermato Venereologica · doi:10.2340/00015555-1931 · Cited by 65
Galluzzo, M., Talamonti, M., SIMONE, C. D., D’Adamio, S., Moretta, G., Tambone, S., Caldarola, G., Fargnoli, M. C., Peris, K., & Bianchi, L. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1481503 · Cited by 65
Gaowa, S., Zhou, W., Yu, L., Zhou, X., Liao, K., Yang, K., Lu, Z., Jiang, H., & Chen, X. (2014) · Mediators of Inflammation · doi:10.1155/2014/247372 · Cited by 65
Shu, W., Li, H., Gong, H., Zhang, M., Niu, X., Ma, Y., Zhang, X., Cai, W., Yang, G.-H., Wei, M., et al. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6217 · Cited by 77
“IL-17A is a cytokine produced by numerous cell types, including T-helper type 17 (Th17) cells (41).”
Interleukin-17 in Liver Disease Pathogenesis
Li, N., Yamamoto, G., Fuji, H., & Kisseleva, T. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730926 · Cited by 74
Ankylosing Spondylitis: From Cells to Genes
Zambrano‐Zaragoza, J. F., Agraz‐Cibrián, J. M., González‐Reyes, C., Durán‐Avelar, M. D. J., & Vibanco‐Pérez, N. (2013) · International Journal of Inflammation · doi:10.1155/2013/501653 · Cited by 75
“The role of IL-17 in rheumatic diseases has been ascertained on the basis of findings that indicate that IL-17 promotes cartilage damage in a murine model [40].”
BackgroundAdvances in T Helper 17 Cell Biology: Pathogenic Role and Potential Therapy in Multiple Sclerosis
Volpe, E., Battistini, L., & Borsellino, G. (2015) · Mediators of Inflammation · doi:10.1155/2015/475158 · Cited by 70
“Secukinumab (AIN457) Neutralizes IL-17A NCT01708603 63% reduction of new MRI lesions compared to placebo; ARR reduction not statistically significant [71]”
BackgroundMaekawa, T., Briones, R. A., Resuello, R. R. G., Tuplano, J. V., Hajishengallis, E., Kajikawa, T., Koutsogiannaki, S., Garcia, C. A. G., Ricklin, D., Lambris, J. D., et al. (2016) · Journal of Clinical Periodontology · doi:10.1111/jcpe.12507 · Cited by 64
“In contrast, the GCF levels of osteoprotegerin (OPG), a natural antagonist of RANKL (Bostanci et al. 2007, Miossec & Kolls 2012), were increased upon Cp40 treatment relative to baseline (Fig.”
Liukkonen, J., Gürsoy, U. K., Pussinen, P. J., Suominen, A. L., & Könönen, E. (2016) · Journal of Periodontology · doi:10.1902/jop.2016.160146 · Cited by 63
Li, X., Anderson, M. D., Collin, D., Muegge, I., Wan, J., Brennan, D. L., Kugler, S. Z., Terenzio, D., Kennedy, C., Lin, S., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.789024 · Cited by 67
Intestinal commensal microbiota and cytokines regulate Fut2 + Paneth cells for gut defense
Kamioka, M., Goto, Y., Nakamura, K., Yokoi, Y., Sugimoto, R., Ohira, S., Kurashima, Y., Umemoto, S., Sato, S., Kunisawa, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2115230119 · Cited by 62
“We therefore examined the involvement of IL-17a in α-defensin production by Paneth cells, because IL-17a produced by Th17 cells has been shown to play a critical role in the regulation of the gut immune system (36).”
BackgroundFeng, Y., Chen, Z., Tu, S.-Q., Wei, J.-M., Hou, Y., Kuang, Z., Kang, X.-N., & Ai, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862415 · Cited by 71
IL-17 promotes osteoclast-induced bone loss by regulating glutamine-dependent energy metabolism
Peng, R., Dong, Y., Zheng, M., Kang, H., Wang, P., Zhu, M., Song, K., Wu, W., & Li, F. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06475-2 · Cited by 69
Alterations in peripheral T cell and B cell subsets in patients with osteoarthritis
Zhu, W., Zhang, X., Jiang, Y., Liu, X., Huang, L., Wei, Q., Huang, Y., Wu, W., & Gu, J. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04768-y · Cited by 67
Yang, X., Zhan, N., Jin, Y., Ling, H., Xiao, C., Xie, Z., Zhong, H., Yu, X., Tang, R., Ma, J., et al. (2020) · Theranostics · doi:10.7150/thno.47860 · Cited by 65
“Although the precise pathogenesis of RA remains unclear, the majority of available evidence points out that one pathology in RA is induced by IL-17 signaling and that IL-17 expression is increased during RA [4, 5].”
BackgroundInvolvement of IL-17 in Secondary Brain Injury After a Traumatic Brain Injury in Rats
Tan, L., Zhang, Y., Han, D., Hua, R., Guo, B., Hu, S.-Q., Yan, X., & Xu, T. J. (2017) · NeuroMolecular Medicine · doi:10.1007/s12017-017-8468-4 · Cited by 67
“…Xuzhou 221002, China 3 Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou 221004, China 4 Jiangsu Province Second Hospital of TCM, Nanjing University of Traditional Chinese Medicine, Nanjing 210017, China F, with IL-17A being the prototype (Miossec and Kolls 2012).”
BackgroundConti, H. R., Whibley, N., Coleman, B. M., Garg, A. V., Jaycox, J. R., & Gaffen, S. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122807 · Cited by 57
“It is not yet clear to what extent therapeutic manipulation of the IL-17RA pathway will cause candidiasis, but this issue is obviously of clinical concern [16].”
BackgroundTamassia, N., Arruda-Silva, F., Calzetti, F., Lonardi, S., Gasperini, S., Gardiman, E., Bianchetto-Aguilera, F. M., Gatta, L. B., Girolomoni, G., Mantovani, A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00795 · Cited by 63
“The latter observations hence make IL-17A/F as a very important target for the development of new therapies (1, 8).”
BackgroundThe intestinal and biliary microbiome in autoimmune liver disease—current evidence and concepts
Liwinski, T., Heinemann, M., & Schramm, C. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00936-6 · Cited by 64
“, NF‐κB); together, these processes result in inflammatory cytokine expression and type I interferon production [32].”
BackgroundT helper 17 (Th17) cell responses to the gut microbiota in human diseases
Sun, C., Yang, N. Y., Zheng, Z., Liu, D., & Xu, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114483 · Cited by 65
Xia, W., Bai, J., Wu, X., Wei, Y. Z., Feng, S., Li, L., Zhang, J., Xiong, G., Fan, Y., Shi, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098915 · Cited by 60
“airway structural cells and stimulating innate immunity to mediate neutrophil recruitment in asthma and other airway diseases [7].”
BackgroundImplication of IL-17 in Bone Loss and Structural Damage in Inflammatory Rheumatic Diseases
Goff, B. L., Bouvard, B., Lequerré, T., Lespessailles, É., Marotte, H., Pers, Y., & Cortet, B. (2019) · Mediators of Inflammation · doi:10.1155/2019/8659302 · Cited by 66
“Secreted by many cell types (neutrophils, mast cells, Th17, gamma-delta T cells, NKT, and ILC3), IL-17A promotes the production and releasing of other proinflammatory cytokines from chondrocytes and synovial fibroblasts [8].”
BackgroundT Helper 17 Cells as Pathogenic Drivers of Periodontitis
Dutzan, N., & Abusleme, L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-28524-1_9 · Cited by 63
Naghib, S. M., Ahmadi, B., Kangarshahi, B. M., & Mozafari, M. R. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134542 · Cited by 64
Microbiome’s role in musculoskeletal health through the gut-bone axis insights
Li, Z., Wang, Q., Huang, X., Wu, Y., & Shan, D. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2410478 · Cited by 64
“106,107 Regulatory T cells (Tregs) regulate immune responses negatively by secreting anti-inflammatory cytokines like IL-10 and TGF-β; however, in RA patients, the quantity or function of Treg cells may be impaired.”
BackgroundHu, M. H., Zheng, Q. F., Jia, X. Z., Li, Y., Dong, Y. C., Wang, C. Y., Lin, Q. Y., Zhang, F. Y., Zhao, R. B., Xu, H. W., et al. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12219 · Cited by 57
Th17-Associated Cytokines as a Therapeutic Target for Steroid-Insensitive Asthma
Morishima, Y., Ano, S., Ishii, Y., Ohtsuka, S., Matsuyama, M., Kawaguchi, M., & Hizawa, N. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/609395 · Cited by 61
“Clinical trials using a monoclonal antibody against the p19 subunit of IL-23, expected to specifically inhibit IL-23, are underway to evaluate its efficacy in patients with plaque psoriasis and rheumatoid arthritis [75].”
BackgroundResultInfluentialIL-17A impairs host tolerance during airway chronic infection by Pseudomonas aeruginosa
Lorè, N. I., Cigana, C., Riva, C., Fino, I. D., Nonis, A., Spagnuolo, L., Sipione, B., Cariani, L., Girelli, D., Rossi, G., et al. (2016) · Scientific Reports · doi:10.1038/srep25937 · Cited by 60
IL‐17 alters the mesenchymal stem cell niche towards osteogenesis in cooperation with osteocytes
Liao, C., Zhang, C., Jin, L., & Yang, Y. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29323 · Cited by 59
“IL‐17 receptor A (IL‐17RA) is particularly highly expressed on MSCs, in both humans and mice (Miossec & Kolls, 2012; Osta, Lavocat, Eljaafari, & Miossec, 2014).”
BackgroundOrchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action
Noor, A. A. M., Azlan, M., & Redzwan, N. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020498 · Cited by 66
Secukinumab: A New Treatment Option for Psoriatic Arthritis
Mease, P. J., & McInnes, I. B. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0031-5 · Cited by 58
“Consequently, biological therapies targeting the IL-17 pathway, including antibodies against IL-17A (secukinumab and ixekizumab) and IL-17RA (brodalumab), have been extensively evaluated in psoriasis, PsA, and other spondyloarthritides [29].”
BackgroundBrothers in Arms: Th17 and Treg Responses in Candida albicans Immunity
Whibley, N., & Gaffen, S. L. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004456 · Cited by 60
“impairments in the IL-17 pathway may be at increased risk for disseminated candidiasis, an issue that will need to be monitored, particularly considering the impending use of anti-IL-17 biologic therapy for autoimmunity [16].”
BackgroundLiu, L., Zhou, F., Pin, W., Yu, L., Ma, Z., Li, Y., Gao, D., Zhang, Q., Li, L., & Yu, Z. (2017) · Mediators of Inflammation · doi:10.1155/2017/5309081 · Cited by 63
“As reported, while Th1 subset controls intracellular bacterial infections, the Th2 subset controls parasitic infections and the Th17 subset controls fungal and extracellular bacterial infections, respectively [18].”
BackgroundGilbert, S. J., Bonnet, C. S., Stadnik, P., Duance, V. C., Mason, D. J., & Blain, E. J. (2018) · Journal of Orthopaedic Research® · doi:10.1002/jor.23872 · Cited by 60
Osta, B., Roux, J.-P., Lavocat, F., Pierre, M., Ndongo-Thiam, N., Boivin, G., & Miossec, P. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00151 · Cited by 61
“Blocking of bone-derived endogenous IL-17A with specific inhibitors resulted in a protective inhibition of bone destruction (17, 44).”
BackgroundSelf-citationChiliveru, S., Rahbek, S. H., Jensen, S. K., Jørgensen, S. E., Nissen, S. K., Christiansen, S. H., Mogensen, T. H., Jakobsen, M. R., Iversen, L., Johansen, C., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302120 · Cited by 58
“Most notably, psoriasis is characterized by infiltration of Th17 cells, which stimulate the pathogenic development of inflammation (2, 3).”
Background
Metadata
- Authors
- Miossec, P., & Kolls, J. K.
- Affiliations
- Lyon 1 Université (FR)
- University of Pittsburgh (US)
- Corresponding author
- Miossec, Pierre
- Kolls, Jay K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-10
- Volume
- 11
- Issue
- 10
- Pages
- 763-776
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2022917731
- Cited by
- 1,414
- References
- 169
- Citations by year
- 2026: 74 · 2025: 104 · 2024: 137 · 2023: 101 · 2022: 121 · 2021: 129 · 2020: 97 · 2019: 91 · 2018: 67 · 2017: 114 · 2016: 100 · 2015: 109 · 2014: 97 · 2013: 72 · 2012: 1
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Universitaire de France
- Institut Mérieux
- National Heart, Lung, and Blood Institute (R37HL079142)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- IL-17, Th17 cells, IL-17 inhibitors, IL-23, IL-17 receptor A, psoriasis, rheumatoid arthritis, ankylosing spondylitis, chronic inflammation, autoimmunity, biologic therapy, IL-17A
- MeSH terms
- Animals, Chronic Disease, Humans, Inflammation, Drug Delivery Systems, Interleukin-17, Receptors, Interleukin-17, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.